+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Beta Interferon Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Beta Interferon Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
New

Beta Interferon Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 191 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 6084201
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Beta Interferon Market grew from USD 3.62 billion in 2024 to USD 3.84 billion in 2025. It is expected to continue growing at a CAGR of 5.93%, reaching USD 5.12 billion by 2030.

The therapeutic landscape for beta interferon has undergone significant evolution, driven by advances in molecular biology and a deeper understanding of immune modulation. Historically, beta interferons emerged as first-line treatments for multiple sclerosis, offering a means to slow disease progression through immunoregulatory mechanisms. Over the last decade, these biologics have shifted from niche applications to a broader spectrum of autoimmune and oncology indications, reflecting their versatile anti-inflammatory and antiproliferative properties.

As the market matures, competition has intensified with the entry of biosimilar versions, prompting originator manufacturers to enhance delivery systems, improve patient adherence, and reduce injection-related discomfort. Furthermore, regulatory approvals for new indications have expanded the potential patient pool, while innovations in administration routes-from traditional injections to advanced infusion devices-have elevated the premium on ease of use.

Today, industry stakeholders must navigate a multifaceted environment where clinical efficacy, cost containment, and patient experience converge. This report’s executive summary will explore foundational shifts in the beta interferon space, examine the impact of recent trade policies, uncover critical segmentation insights, assess regional dynamics, spotlight leading companies, and present actionable recommendations for decision-makers. By synthesizing these elements, readers will gain a comprehensive understanding of the forces shaping the future of beta interferon therapeutics.

Transformative Shifts Redefining the Beta Interferon Market

The beta interferon market has witnessed transformative shifts driven by scientific innovations, regulatory reforms, and patient-centric care models. Initially anchored in injectable therapies for multiple sclerosis, the field has expanded to include hepatocellular carcinoma and rheumatoid arthritis indications, unlocking new pathways for immune modulation.

Advancements in recombinant DNA technology have lowered manufacturing costs and facilitated the development of high-purity interferon beta variants. Concurrently, regulatory agencies have introduced accelerated approval pathways for treatments addressing unmet medical needs, expediting market access for novel formulations. Patients now benefit from subcutaneous auto-injectors and prefabricated syringes designed to minimize injection-site reactions and enhance adherence.

In parallel, the rise of biosimilars has intensified price competition, compelling originator firms to invest in value-added services such as homecare support and digital adherence platforms. Health systems are increasingly adopting outcome-based contracts to align pricing with real-world performance, fostering a data-driven approach to therapy selection. Additionally, collaborative efforts between pharmaceutical companies and technology providers have produced automated delivery solutions including smart pens and infusion pumps, further improving patient convenience.

Together, these developments signify a shift from commoditized injectables to integrated therapeutic ecosystems, where clinical efficacy, patient experience, and economic sustainability are deeply intertwined.

Cumulative Impact of United States Tariffs on Beta Interferon Production

United States tariff adjustments announced for 2025 have begun to reshape the importation dynamics of biologic intermediates and finished products. Higher duties on certain enzyme and cell culture reagents have elevated downstream production costs for manufacturers relying on overseas supply chains. In response, several firms have initiated strategic stockpiling of key raw materials to hedge against further escalations and mitigate supply disruptions.

Simultaneously, tariffs on single-use bioprocessing equipment have increased capital expenditure, prompting companies to accelerate plans for domestic manufacturing capacity expansion. A number of contract manufacturing organizations are investing in state-of-the-art facilities within the U.S. to circumvent import levies and ensure uninterrupted supply of both originator and biosimilar interferons.

Moreover, the tariff landscape has spurred localized innovation in formulation and delivery technologies. By reducing reliance on imported packaging components and transitioning to modular assembly of auto-injectors and pre-filled syringes within domestic plants, companies can optimize cost structures and maintain competitive pricing. As a result, the cumulative effect of these policies extends beyond mere cost inflation; it is catalyzing a realignment of manufacturing footprints and value chains across the beta interferon sector.

Key Segmentation Insights Shaping Beta Interferon Usage

Insights into the beta interferon market reveal differentiated growth trajectories across applications, administration routes, product types, end-users, delivery modes, and patient demographics. When segmenting by application, multiple sclerosis remains the cornerstone, with relapsing-remitting, primary progressive, and secondary progressive subtypes driving varied clinical protocols, while hepatocellular carcinoma’s advanced and localized treatment phases are opening oncology adjacencies. Rheumatoid arthritis, spanning adult-onset and juvenile presentations, continues to leverage interferon’s immunomodulatory effects in specialized care settings.

Considering administration routes, subcutaneous injections delivered via auto-injectors or pre-filled syringes have gained traction for self-administration, whereas bolus injections and continuous infusions through intravenous lines remain integral in hospital and specialty clinic environments. The product-type segmentation underscores a shift toward biosimilar interferons-both beta-1a and beta-1b variants-as cost-effective alternatives, even as originator biological drugs maintain a premium positioning based on extensive clinical track records.

From an end-user perspective, hospitals-both private and public-serve as primary infusion centers, while outpatient and specialty clinics cater to routine subcutaneous dosing. Homecare settings, featuring assisted administration and fully self-administered protocols, are rising in prominence, reflecting patient preference for convenience. In terms of delivery mode, automated solutions such as infusion pumps and smart pens are redefining user experience, while manual pens and syringes remain relevant for low-frequency dosing. Lastly, adults aged 18 to 45 and those over 46 constitute the largest patient cohorts, yet pediatrics, subdivided into ages zero to twelve and thirteen to seventeen, represent a critical emerging segment necessitating tailored dosing strategies.

Key Regional Insights on Beta Interferon Adoption

Regional analysis illustrates distinctive adoption patterns and growth drivers for beta interferon therapies. In the Americas, robust reimbursement frameworks and established multiple sclerosis care networks have sustained strong demand, particularly in the U.S. and Canada, where patient advocacy groups influence formulary decisions. Conversely, Latin American markets are gradually building the infrastructure for biologic distribution, with emerging local manufacturing collaborations poised to improve accessibility.

In Europe, Middle East & Africa, heterogeneity in healthcare funding and regulatory environments creates a mosaic of uptake rates. Western Europe’s mature markets feature high competition among biosimilars, while Eastern Europe and select Middle Eastern countries are benefiting from patient support programs that bridge affordability gaps. Across Africa, access remains limited by logistic constraints, yet regional partnerships with international donors and NGOs are laying the groundwork for expanded interferon distribution.

The Asia-Pacific region exhibits dynamic growth, fueled by expanding healthcare budgets in China, India, and Southeast Asia. Localized production of biosimilars, combined with government initiatives to include chronic disease treatments in national insurance schemes, is accelerating adoption. Australia and Japan continue to prioritize originator interferons, leveraging stringent regulatory standards and well-developed specialty care networks.

Key Company Insights in the Beta Interferon Ecosystem

Leading life sciences companies are actively shaping the beta interferon market through innovation, strategic alliances, and portfolio diversification. Amega Biotech and Biosidus S.A. are enhancing biosimilar pipelines, targeting cost-sensitive markets with Interferon Beta-1a and Beta-1b analogues, while Avantor, Inc. and Thermo Fisher Scientific Inc. focus on supplying critical bioprocessing reagents and single-use technologies tailored for interferon manufacture.

Originator firms such as Bayer AG, Biogen Inc., F. Hoffmann-La Roche Ltd., and Novartis AG continue to leverage extensive clinical datasets and patient support ecosystems to defend market share. Merck KGaA, through investments in smart pen delivery and digital adherence platforms, and Pfizer Inc., with its robust infusion pump solutions, are forging partnerships to integrate therapeutics with connected health.

In parallel, smaller specialist firms like BioLegend, Inc. by PerkinElmer Inc., Faron Pharmaceuticals, Heligenics, Inc., Qiagen GmbH, Sino Biological, Inc., Synairgen PLC, and Xiamen Amoytop Biotech Co., Ltd. are driving niche advancements ranging from assay development to novel formulation techniques. OriGene Technologies, Inc. complements this landscape by offering genetic and reagent services that support interferon research and diagnostic applications.

Actionable Recommendations for Industry Leaders

Industry leaders should adopt a multi-pronged strategy to capitalize on emerging opportunities and mitigate evolving risks. Prioritizing vertical integration can buffer against tariff-induced cost volatility by securing local production of key raw materials and delivery components. Moreover, forging collaborations with digital health providers will enhance patient engagement through adherence monitoring and telemedicine-supported administration, thereby differentiating offerings in saturated markets.

It is also crucial to align pricing models with value-based care initiatives. By partnering with payers to implement outcome-driven contracts tied to real-world effectiveness, companies can justify premium pricing for advanced formulations and automated delivery systems. Investing in educational programs for healthcare professionals and patient communities will further solidify market positioning, ensuring that treatment protocols reflect the latest clinical guidelines.

Finally, expanding into underserved regions via strategic alliances with regional distributors and non-profit organizations can unlock new patient populations. By deploying scalable infrastructure for both originator and biosimilar interferons, firms can foster equitable access while building brand loyalty and long-term growth potential.

Conclusion: Navigating the Next Phase of Beta Interferon Therapy

The beta interferon market stands at a pivotal juncture where strategic foresight and operational agility will determine long-term success. Companies that effectively integrate manufacturing resilience, digital innovation, and patient-centric value propositions will outperform in an increasingly competitive environment. By proactively addressing tariff challenges, optimizing segmentation strategies, and extending their global footprints, stakeholders can solidify leadership and deliver meaningful improvements in patient care.

Market Segmentation & Coverage

This research report categorizes the Beta Interferon Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Hepatocellular Carcinoma
    • Advanced Treatment Phase
    • Localized Treatment Phase
  • Multiple Sclerosis
    • Primary Progressive Multiple Sclerosis
    • Relapsing-Remitting Multiple Sclerosis
    • Secondary Progressive Multiple Sclerosis
  • Rheumatoid Arthritis
    • Adult Onset
    • Juvenile Arthritis
  • Intravenous
    • Bolus Injection
    • Continuous Infusion
  • Subcutaneous
    • Auto-Injectors
    • Pre-Filled Syringes
  • Biosimilars
    • Interferon Beta-1a Biosimilar
    • Interferon Beta-1b Biosimilar
  • Originator Biological Products
    • Biological Drugs
  • Clinics
    • Outpatient Clinics
    • Specialty Clinics
  • Homecare Settings
    • Assisted Administration
    • Self-Administration
  • Hospitals
    • Private Hospitals
    • Public Hospitals
  • Automated Delivery
    • Infusion Pumps
    • Smart Pen Delivery Systems
  • Manual Delivery
    • Pens
    • Syringes
  • Adults
    • Aged 18-45
    • Aged 46 and above
  • Pediatrics
    • Aged 0-12
    • Aged 13-17

This research report categorizes the Beta Interferon Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Beta Interferon Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Amega Biotech
  • Avantor, Inc.
  • Bayer AG
  • Biogen Inc.
  • BioLegend, Inc. by PerkinElmer Inc.
  • Biosidus S.A
  • F. Hoffmann La-Roche Ltd.
  • Faron Pharmaceuticals
  • Heligenics, Inc.
  • Merck KGaA
  • Novartis AG
  • OriGene Technologies, Inc.
  • Pfizer Inc.
  • Qiagen GmbH
  • Sino Biological, Inc.
  • Synairgen PLC
  • Thermo Fisher Scientific Inc.
  • Xiamen Amoytop Biotech Co., Ltd.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Beta Interferon Market, by Application
8.1. Introduction
8.2. Hepatocellular Carcinoma
8.2.1. Advanced Treatment Phase
8.2.2. Localized Treatment Phase
8.3. Multiple Sclerosis
8.3.1. Primary Progressive Multiple Sclerosis
8.3.2. Relapsing-Remitting Multiple Sclerosis
8.3.3. Secondary Progressive Multiple Sclerosis
8.4. Rheumatoid Arthritis
8.4.1. Adult Onset
8.4.2. Juvenile Arthritis
9. Beta Interferon Market, by Route of Administration
9.1. Introduction
9.2. Intravenous
9.2.1. Bolus Injection
9.2.2. Continuous Infusion
9.3. Subcutaneous
9.3.1. Auto-Injectors
9.3.2. Pre-Filled Syringes
10. Beta Interferon Market, by Type of Product
10.1. Introduction
10.2. Biosimilars
10.2.1. Interferon Beta-1a Biosimilar
10.2.2. Interferon Beta-1b Biosimilar
10.3. Originator Biological Products
10.3.1. Biological Drugs
11. Beta Interferon Market, by End-User
11.1. Introduction
11.2. Clinics
11.2.1. Outpatient Clinics
11.2.2. Specialty Clinics
11.3. Homecare Settings
11.3.1. Assisted Administration
11.3.2. Self-Administration
11.4. Hospitals
11.4.1. Private Hospitals
11.4.2. Public Hospitals
12. Beta Interferon Market, by Mode of Delivery
12.1. Introduction
12.2. Automated Delivery
12.2.1. Infusion Pumps
12.2.2. Smart Pen Delivery Systems
12.3. Manual Delivery
12.3.1. Pens
12.3.2. Syringes
13. Beta Interferon Market, by Patient Demographics
13.1. Introduction
13.2. Adults
13.2.1. Aged 18-45
13.2.2. Aged 46 and above
13.3. Pediatrics
13.3.1. Aged 0-12
13.3.2. Aged 13-17
14. Americas Beta Interferon Market
14.1. Introduction
14.2. Argentina
14.3. Brazil
14.4. Canada
14.5. Mexico
14.6. United States
15. Asia-Pacific Beta Interferon Market
15.1. Introduction
15.2. Australia
15.3. China
15.4. India
15.5. Indonesia
15.6. Japan
15.7. Malaysia
15.8. Philippines
15.9. Singapore
15.10. South Korea
15.11. Taiwan
15.12. Thailand
15.13. Vietnam
16. Europe, Middle East & Africa Beta Interferon Market
16.1. Introduction
16.2. Denmark
16.3. Egypt
16.4. Finland
16.5. France
16.6. Germany
16.7. Israel
16.8. Italy
16.9. Netherlands
16.10. Nigeria
16.11. Norway
16.12. Poland
16.13. Qatar
16.14. Russia
16.15. Saudi Arabia
16.16. South Africa
16.17. Spain
16.18. Sweden
16.19. Switzerland
16.20. Turkey
16.21. United Arab Emirates
16.22. United Kingdom
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Amega Biotech
17.3.2. Avantor, Inc.
17.3.3. Bayer AG
17.3.4. Biogen Inc.
17.3.5. BioLegend, Inc. by PerkinElmer Inc.
17.3.6. Biosidus S.A
17.3.7. F. Hoffmann La-Roche Ltd.
17.3.8. Faron Pharmaceuticals
17.3.9. Heligenics, Inc.
17.3.10. Merck KGaA
17.3.11. Novartis AG
17.3.12. OriGene Technologies, Inc.
17.3.13. Pfizer Inc.
17.3.14. Qiagen GmbH
17.3.15. Sino Biological, Inc.
17.3.16. Synairgen PLC
17.3.17. Thermo Fisher Scientific Inc.
17.3.18. Xiamen Amoytop Biotech Co., Ltd.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. BETA INTERFERON MARKET MULTI-CURRENCY
FIGURE 2. BETA INTERFERON MARKET MULTI-LANGUAGE
FIGURE 3. BETA INTERFERON MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BETA INTERFERON MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BETA INTERFERON MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BETA INTERFERON MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BETA INTERFERON MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BETA INTERFERON MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BETA INTERFERON MARKET SIZE, BY TYPE OF PRODUCT, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BETA INTERFERON MARKET SIZE, BY TYPE OF PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BETA INTERFERON MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BETA INTERFERON MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BETA INTERFERON MARKET SIZE, BY MODE OF DELIVERY, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BETA INTERFERON MARKET SIZE, BY MODE OF DELIVERY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL BETA INTERFERON MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
FIGURE 18. GLOBAL BETA INTERFERON MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS BETA INTERFERON MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS BETA INTERFERON MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES BETA INTERFERON MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES BETA INTERFERON MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC BETA INTERFERON MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC BETA INTERFERON MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA BETA INTERFERON MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA BETA INTERFERON MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. BETA INTERFERON MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. BETA INTERFERON MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BETA INTERFERON MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BETA INTERFERON MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BETA INTERFERON MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BETA INTERFERON MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BETA INTERFERON MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BETA INTERFERON MARKET SIZE, BY ADVANCED TREATMENT PHASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BETA INTERFERON MARKET SIZE, BY LOCALIZED TREATMENT PHASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BETA INTERFERON MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BETA INTERFERON MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BETA INTERFERON MARKET SIZE, BY PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BETA INTERFERON MARKET SIZE, BY RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BETA INTERFERON MARKET SIZE, BY SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BETA INTERFERON MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BETA INTERFERON MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BETA INTERFERON MARKET SIZE, BY ADULT ONSET, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BETA INTERFERON MARKET SIZE, BY JUVENILE ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BETA INTERFERON MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BETA INTERFERON MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BETA INTERFERON MARKET SIZE, BY BOLUS INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BETA INTERFERON MARKET SIZE, BY CONTINUOUS INFUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BETA INTERFERON MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BETA INTERFERON MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BETA INTERFERON MARKET SIZE, BY AUTO-INJECTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BETA INTERFERON MARKET SIZE, BY PRE-FILLED SYRINGES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BETA INTERFERON MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BETA INTERFERON MARKET SIZE, BY TYPE OF PRODUCT, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BETA INTERFERON MARKET SIZE, BY BIOSIMILARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BETA INTERFERON MARKET SIZE, BY INTERFERON BETA-1A BIOSIMILAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BETA INTERFERON MARKET SIZE, BY INTERFERON BETA-1B BIOSIMILAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BETA INTERFERON MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BETA INTERFERON MARKET SIZE, BY ORIGINATOR BIOLOGICAL PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BETA INTERFERON MARKET SIZE, BY BIOLOGICAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BETA INTERFERON MARKET SIZE, BY ORIGINATOR BIOLOGICAL PRODUCTS, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BETA INTERFERON MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BETA INTERFERON MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BETA INTERFERON MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BETA INTERFERON MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BETA INTERFERON MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BETA INTERFERON MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BETA INTERFERON MARKET SIZE, BY ASSISTED ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BETA INTERFERON MARKET SIZE, BY SELF-ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BETA INTERFERON MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BETA INTERFERON MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BETA INTERFERON MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BETA INTERFERON MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BETA INTERFERON MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BETA INTERFERON MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BETA INTERFERON MARKET SIZE, BY AUTOMATED DELIVERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BETA INTERFERON MARKET SIZE, BY INFUSION PUMPS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BETA INTERFERON MARKET SIZE, BY SMART PEN DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BETA INTERFERON MARKET SIZE, BY AUTOMATED DELIVERY, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL BETA INTERFERON MARKET SIZE, BY MANUAL DELIVERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL BETA INTERFERON MARKET SIZE, BY PENS, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL BETA INTERFERON MARKET SIZE, BY SYRINGES, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL BETA INTERFERON MARKET SIZE, BY MANUAL DELIVERY, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL BETA INTERFERON MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL BETA INTERFERON MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL BETA INTERFERON MARKET SIZE, BY AGED 18-45, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL BETA INTERFERON MARKET SIZE, BY AGED 46 AND ABOVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL BETA INTERFERON MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL BETA INTERFERON MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL BETA INTERFERON MARKET SIZE, BY AGED 0-12, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL BETA INTERFERON MARKET SIZE, BY AGED 13-17, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL BETA INTERFERON MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS BETA INTERFERON MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS BETA INTERFERON MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS BETA INTERFERON MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS BETA INTERFERON MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS BETA INTERFERON MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS BETA INTERFERON MARKET SIZE, BY TYPE OF PRODUCT, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS BETA INTERFERON MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS BETA INTERFERON MARKET SIZE, BY ORIGINATOR BIOLOGICAL PRODUCTS, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS BETA INTERFERON MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS BETA INTERFERON MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS BETA INTERFERON MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS BETA INTERFERON MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS BETA INTERFERON MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS BETA INTERFERON MARKET SIZE, BY AUTOMATED DELIVERY, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS BETA INTERFERON MARKET SIZE, BY MANUAL DELIVERY, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS BETA INTERFERON MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS BETA INTERFERON MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS BETA INTERFERON MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS BETA INTERFERON MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA BETA INTERFERON MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA BETA INTERFERON MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA BETA INTERFERON MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA BETA INTERFERON MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA BETA INTERFERON MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA BETA INTERFERON MARKET SIZE, BY TYPE OF PRODUCT, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA BETA INTERFERON MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA BETA INTERFERON MARKET SIZE, BY ORIGINATOR BIOLOGICAL PRODUCTS, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA BETA INTERFERON MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA BETA INTERFERON MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA BETA INTERFERON MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA BETA INTERFERON MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA BETA INTERFERON MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA BETA INTERFERON MARKET SIZE, BY AUTOMATED DELIVERY, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA BETA INTERFERON MARKET SIZE, BY MANUAL DELIVERY, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA BETA INTERFERON MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA BETA INTERFERON MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA BETA INTERFERON MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL BETA INTERFERON MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL BETA INTERFERON MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL BETA INTERFERON MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL BETA INTERFERON MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL BETA INTERFERON MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL BETA INTERFERON MARKET SIZE, BY TYPE OF PRODUCT, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL BETA INTERFERON MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL BETA INTERFERON MARKET SIZE, BY ORIGINATOR BIOLOGICAL PRODUCTS, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL BETA INTERFERON MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL BETA INTERFERON MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL BETA INTERFERON MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL BETA INTERFERON MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL BETA INTERFERON MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL BETA INTERFERON MARKET SIZE, BY AUTOMATED DELIVERY, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL BETA INTERFERON MARKET SIZE, BY MANUAL DELIVERY, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL BETA INTERFERON MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL BETA INTERFERON MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL BETA INTERFERON MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 129. CANADA BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 130. CANADA BETA INTERFERON MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, 2018-2030 (USD MILLION)
TABLE 131. CANADA BETA INTERFERON MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2030 (USD MILLION)
TABLE 132. CANADA BETA INTERFERON MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 133. CANADA BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 134. CANADA BETA INTERFERON MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 135. CANADA BETA INTERFERON MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 136. CANADA BETA INTERFERON MARKET SIZE, BY TYPE OF PRODUCT, 2018-2030 (USD MILLION)
TABLE 137. CANADA BETA INTERFERON MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 138. CANADA BETA INTERFERON MARKET SIZE, BY ORIGINATOR BIOLOGICAL PRODUCTS, 2018-2030 (USD MILLION)
TABLE 139. CANADA BETA INTERFERON MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 140. CANADA BETA INTERFERON MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 141. CANADA BETA INTERFERON MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 142. CANADA BETA INTERFERON MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 143. CANADA BETA INTERFERON MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 144. CANADA BETA INTERFERON MARKET SIZE, BY AUTOMATED DELIVERY, 2018-2030 (USD MILLION)
TABLE 145. CANADA BETA INTERFERON MARKET SIZE, BY MANUAL DELIVERY, 2018-2030 (USD MILLION)
TABLE 146. CANADA BETA INTERFERON MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 147. CANADA BETA INTERFERON MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 148. CANADA BETA INTERFERON MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 149. MEXICO BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 150. MEXICO BETA INTERFERON MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, 2018-2030 (USD MILLION)
TABLE 151. MEXICO BETA INTERFERON MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2030 (USD MILLION)
TABLE 152. MEXICO BETA INTERFERON MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 153. MEXICO BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 154. MEXICO BETA INTERFERON MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 155. MEXICO BETA INTERFERON MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 156. MEXICO BETA INTERFERON MARKET SIZE, BY TYPE OF PRODUCT, 2018-2030 (USD MILLION)
TABLE 157. MEXICO BETA INTERFERON MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 158. MEXICO BETA INTERFERON MARKET SIZE, BY ORIGINATOR BIOLOGICAL PRODUCTS, 2018-2030 (USD MILLION)
TABLE 159. MEXICO BETA INTERFERON MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 160. MEXICO BETA INTERFERON MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 161. MEXICO BETA INTERFERON MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 162. MEXICO BETA INTERFERON MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 163. MEXICO BETA INTERFERON MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 164. MEXICO BETA INTERFERON MARKET SIZE, BY AUTOMATED DELIVERY, 2018-2030 (USD MILLION)
TABLE 165. MEXICO BETA INTERFERON MARKET SIZE, BY MANUAL DELIVERY, 2018-2030 (USD MILLION)
TABLE 166. MEXICO BETA INTERFERON MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 167. MEXICO BETA INTERFERON MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 168. MEXICO BETA INTERFERON MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 169. UNITED STATES BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 170. UNITED STATES BETA INTERFERON MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, 2018-2030 (USD MILLION)
TABLE 171. UNITED STATES BETA INTERFERON MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2030 (USD MILLION)
TABLE 172. UNITED STATES BETA INTERFERON MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 173. UNITED STATES BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 174. UNITED STATES BETA INTERFERON MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 175. UNITED STATES BETA INTERFERON MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 176. UNITED STATES BETA INTERFERON MARKET SIZE, BY TYPE OF PRODUCT, 2018-2030 (USD MILLION)
TABLE 177. UNITED STATES BETA INTERFERON MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 178. UNITED STATES BETA INTERFERON MARKET SIZE, BY ORIGINATOR BIOLOGICAL PRODUCTS, 2018-2030 (USD MILLION)
TABLE 179. UNITED STATES BETA INTERFERON MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 180. UNITED STATES BETA INTERFERON MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 181. UNITED STATES BETA INTERFERON MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 182. UNITED STATES BETA INTERFERON MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 183. UNITED STATES BETA INTERFERON MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 184. UNITED STATES BETA INTERFERON MARKET SIZE, BY AUTOMATED DELIVERY, 2018-2030 (USD MILLION)
TABLE 185. UNITED STATES BETA INTERFERON MARKET SIZE, BY MANUAL DELIVERY, 2018-2030 (USD MILLION)
TABLE 186. UNITED STATES BETA INTERFERON MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 187. UNITED STATES BETA INTERFERON MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 188. UNITED STATES BETA INTERFERON MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 189. UNITED STATES BETA INTERFERON MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 190. ASIA-PACIFIC BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 191. ASIA-PACIFIC BETA INTERFERON MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, 2018-2030 (USD MILLION)
TABLE 192. ASIA-PACIFIC BETA INTERFERON MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2030 (USD MILLION)
TABLE 193. ASIA-PACIFIC BETA INTERFERON MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 194. ASIA-PACIFIC BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 195. ASIA-PACIFIC BETA INTERFERON MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 196. ASIA-PACIFIC BETA INTERFERON MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 197. ASIA-PACIFIC BETA INTERFERON MARKET SIZE, BY TYPE OF PRODUCT, 2018-2030 (USD MILLION)
TABLE 198. ASIA-PACIFIC BETA INTERFERON MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 199. ASIA-PACIFIC BETA INTERFERON MARKET SIZE, BY ORIGINATOR BIOLOGICAL PRODUCTS, 2018-2030 (USD MILLION)
TABLE 200. ASIA-PACIFIC BETA INTERFERON MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 201. ASIA-PACIFIC BETA INTERFERON MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 202. ASIA-PACIFIC BETA INTERFERON MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 203. ASIA-PACIFIC BETA INTERFERON MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 204. ASIA-PACIFIC BETA INTERFERON MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 205. ASIA-PACIFIC BETA INTERFERON MARKET SIZE, BY AUTOMATED DELIVERY, 2018-2030 (USD MILLION)
TABLE 206. ASIA-PACIFIC BETA INTERFERON MARKET SIZE, BY MANUAL DELIVERY, 2018-2030 (USD MILLION)
TABLE 207. ASIA-PACIFIC BETA INTERFERON MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 208. ASIA-PACIFIC BETA INTERFERON MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 209. ASIA-PACIFIC BETA INTERFERON MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 210. ASIA-PACIFIC BETA INTERFERON MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 211. AUSTRALIA BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 212. AUSTRALIA BETA INTERFERON MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, 2018-2030 (USD MILLION)
TABLE 213. AUSTRALIA BETA INTERFERON MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2030 (USD MILLION)
TABLE 214. AUSTRALIA BETA INTERFERON MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 215. AUSTRALIA BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 216. AUSTRALIA BETA INTERFERON MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 217. AUSTRALIA BETA INTERFERON MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 218. AUSTRALIA BETA INTERFERON MARKET SIZE, BY TYPE OF PRODUCT, 2018-2030 (USD MILLION)
TABLE 219. AUSTRALIA BETA INTERFERON MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 220. AUSTRALIA BETA INTERFERON MARKET SIZE, BY ORIGINATOR BIOLOGICAL PRODUCTS, 2018-2030 (USD MILLION)
TABLE 221. AUSTRALIA BETA INTERFERON MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 222. AUSTRALIA BETA INTERFERON MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 223. AUSTRALIA BETA INTERFERON MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 224. AUSTRALIA BETA INTERFERON MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 225. AUSTRALIA BETA INTERFERON MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 226. AUSTRALIA BETA INTERFERON MARKET SIZE, BY AUTOMATED DELIVERY, 2018-2030 (USD MILLION)
TABLE 227. AUSTRALIA BETA INTERFERON MARKET SIZE, BY MANUAL DELIVERY, 2018-2030 (USD MILLION)
TABLE 228. AUSTRALIA BETA INTERFERON MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 229. AUSTRALIA BETA INTERFERON MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 230. AUSTRALIA BETA INTERFERON MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 231. CHINA BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 232. CHINA BETA INTERFERON MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, 2018-2030 (USD MILLION)
TABLE 233. CHINA BETA INTERFERON MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2030 (USD MILLION)
TABLE 234. CHINA BETA INTERFERON MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 235. CHINA BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 236. CHINA BETA INTERFERON MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 237. CHINA BETA INTERFERON MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 238. CHINA BETA INTERFERON MARKET SIZE, BY TYPE OF PRODUCT, 2018-2030 (USD MILLION)
TABLE 239. CHINA BETA INTERFERON MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 240. CHINA BETA INTERFERON MARKET SIZE, BY ORIGINATOR BIOLOGICAL PRODUCTS, 2018-2030 (USD MILLION)
TABLE 241. CHINA BETA INTERFERON MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 242. CHINA BETA INTERFERON MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 243. CHINA BETA INTERFERON MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 244. CHINA BETA INTERFERON MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 245. CHINA BETA INTERFERON MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 246. CHINA BETA INTERFERON MARKET SIZE, BY AUTOMATED DELIVERY, 2018-2030 (USD MILLION)
TABLE 247. CHINA BETA INTERFERON MARKET SIZE, BY MANUAL DELIVERY, 2018-2030 (USD MILLION)
TABLE 248. CHINA BETA INTERFERON MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 249. CHINA BETA INTERFERON MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 250. CHINA BETA INTERFERON MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 251. INDIA BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 252. INDIA BETA INTERFERON MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, 2018-2030 (USD MILLION)
TABLE 253. INDIA BETA INTERFERON MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2030 (USD MILLION)
TABLE 254. INDIA BETA INTERFERON MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 255. INDIA BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 256. INDIA BETA INTERFERON MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 257. INDIA BETA INTERFERON MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 258. INDIA BETA INTERFERON MARKET SIZE, BY TYPE OF PRODUCT, 2018-2030 (USD MILLION)
TABLE 259. INDIA BETA INTERFERON MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 260. INDIA BETA INTERFERON MARKET SIZE, BY ORIGINATOR BIOLOGICAL PRODUCTS, 2018-2030 (USD MILLION)
TABLE 261. INDIA BETA INTERFERON MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 262. INDIA BETA INTERFERON MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 263. INDIA BETA INTERFERON MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 264. INDIA BETA INTERFERON MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 265. INDIA BETA INTERFERON MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 266. INDIA BETA INTERFERON MARKET SIZE, BY AUTOMATED DELIVERY, 2018-2030 (USD MILLION)
TABLE 267. INDIA BETA INTERFERON MARKET SIZE, BY MANUAL DELIVERY, 2018-2030 (USD MILLION)
TABLE 268. INDIA BETA INTERFERON MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 269. INDIA BETA INTERFERON MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 270. INDIA BETA INTERFERON MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 271. INDONESIA BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 272. INDONESIA BETA INTERFERON MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, 2018-2030 (USD MILLION)
TABLE 273. INDONESIA BETA INTERFERON MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2030 (USD MILLION)
TABLE 274. INDONESIA BETA INTERFERON MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 275. INDONESIA BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 276. INDONESIA BETA INTERFERON MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 277. INDONESIA BETA INTERFERON MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 278. INDONESIA BETA INTERFERON MARKET SIZE, BY TYPE OF PRODUCT, 2018-2030 (USD MILLION)
TABLE 279. INDONESIA BETA INTERFERON MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 280. INDONESIA BETA INTERFERON MARKET SIZE, BY ORIGINATOR BIOLOGICAL PRODUCTS, 2018-2030 (USD MILLION)
TABLE 281. INDONESIA BETA INTERFERON MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 282. INDONESIA BETA INTERFERON MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 283. INDONESIA BETA INTERFERON MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 284. INDONESIA BETA INTERFERON MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 285. INDONESIA BETA INTERFERON MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 286. INDONESIA BETA INTERFERON MARKET SIZE, BY AUTOMATED DELIVERY, 2018-2030 (USD MILLION)
TABLE 287. INDONESIA BETA INTERFERON MARKET SIZE, BY MANUAL DELIVERY, 2018-2030 (USD MILLION)
TABLE 288. INDONESIA BETA INTERFERON MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 289. INDONESIA BETA INTERFERON MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 290. INDONESIA BETA INTERFERON MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 291. JAPAN BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 292. JAPAN BETA INTERFERON MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, 2018-2030 (USD MILLION)
TABLE 293. JAPAN BETA INTERFERON MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2030 (USD MILLION)
TABLE 294. JAPAN BETA INTERFERON MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 295. JAPAN BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 296. JAPAN BETA INTERFERON MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 297. JAPAN BETA INTERFERON MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 298. JAPAN BETA INTERFERON MARKET SIZE, BY TYPE OF PRODUCT, 2018-2030 (USD MILLION)
TABLE 299. JAPAN BETA INTERFERON MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 300. JAPAN BETA INTERFERON MARKET SIZE, BY ORIGINATOR BIOLOGICAL PRODUCTS, 2018-2030 (USD MILLION)
TABLE 301. JAPAN BETA INTERFERON MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 302. JAPAN BETA INTERFERON MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 303. JAPAN BETA INTERFERON MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 304. JAPAN BETA INTERFERON MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 305. JAPAN BETA INTERFERON MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 306. JAPAN BETA INTERFERON MARKET SIZE, BY AUTOMATED DELIVERY, 2018-2030 (USD MILLION)
TABLE 307. JAPAN BETA INTERFERON MARKET SIZE, BY MANUAL DELIVERY, 2018-2030 (USD MILLION)
TABLE 308. JAPAN BETA INTERFERON MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 309. JAPAN BETA INTERFERON MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 310. JAPAN BETA INTERFERON MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 311. MALAYSIA BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 312. MALAYSIA BETA INTERFERON MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, 2018-2030 (USD MILLION)
TABLE 313. MALAYSIA BETA INTERFERON MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2030 (USD MILLION)
TABLE 314. MALAYSIA BETA INTERFERON MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 315. MALAYSIA BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 316. MALAYSIA BETA INTERFERON MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 317. MALAYSIA BETA INTERFERON MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 318. MALAYSIA BETA INTERFERON MARKET SIZE, BY TYPE OF PRODUCT, 2018-2030 (USD MILLION)
TABLE 319. MALAYSIA BETA INTERFERON MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 320. MALAYSIA BETA INTERFERON MARKET SIZE, BY ORIGINATOR BIOLOGICAL PRODUCTS, 2018-2030 (USD MILLION)
TABLE 321. MALAYSIA BETA INTERFERON MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 322. MALAYSIA BETA INTERFERON MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 323. MALAYSIA BETA INTERFERON MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 324. MALAYSIA BETA INTERFERON MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 325. MALAYSIA BETA INTERFERON MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 326. MALAYSIA BETA INTERFERON MARKET SIZE, BY AUTOMATED DELIVERY, 2018-2030 (USD MILLION)
TABLE 327. MALAYSIA BETA INTERFERON MARKET SIZE, BY MANUAL DELIVERY, 2018-2030 (USD MILLION)
TABLE 328. MALAYSIA BETA INTERFERON MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 329. MALAYSIA BETA INTERFERON MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 330. MALAYSIA BETA INTERFERON MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 331. PHILIPPINES BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 332. PHILIPPINES BETA INTERFERON MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, 2018-2030 (USD MILLION)
TABLE 333. PHILIPPINES BETA INTERFERON MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2030 (USD MILLION)
TABLE 334. PHILIPPINES BETA INTERFERON MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 335. PHILIPPINES BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 336. PHILIPPINES BETA INTERFERON MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 337. PHILIPPINES BETA INTERFERON MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 338. PHILIPPINES BETA INTERFERON MARKET SIZE, BY TYPE OF PRODUCT, 2018-2030 (USD MILLION)
TABLE 339. PHILIPPINES BETA INTERFERON MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 340. PHILIPPINES BETA INTERFERON MARKET SIZE, BY ORIGINATOR BIOLOGICAL PRODUCTS, 2018-2030 (USD MILLION)
TABLE 341. PHILIPPINES BETA INTERFERON MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 342. PHILIPPINES BETA INTERFERON MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 343. PHILIPPINES BETA INTERFERON MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 344. PHILIPPINES BETA INTERFERON MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 345. PHILIPPINES BETA INTERFERON MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 346. PHILIPPINES BETA INTERFERON MARKET SIZE, BY AUTOMATED DELIVERY, 2018-2030 (USD MILLION)
TABLE 347. PHILIPPINES BETA INTERFERON MARKET SIZE, BY MANUAL DELIVERY, 2018-2030 (USD MILLION)
TABLE 348. PHILIPPINES BETA INTERFERON MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 349. PHILIPPINES BETA INTERFERON MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 350. PHILIPPINES BETA INTERFERON MARKET SIZE, BY PEDIATRICS, 2018

Companies Mentioned

  • Amega Biotech
  • Avantor, Inc.
  • Bayer AG
  • Biogen Inc.
  • BioLegend, Inc. by PerkinElmer Inc.
  • Biosidus S.A
  • F. Hoffmann La-Roche Ltd.
  • Faron Pharmaceuticals
  • Heligenics, Inc.
  • Merck KGaA
  • Novartis AG
  • OriGene Technologies, Inc.
  • Pfizer Inc.
  • Qiagen GmbH
  • Sino Biological, Inc.
  • Synairgen PLC
  • Thermo Fisher Scientific Inc.
  • Xiamen Amoytop Biotech Co., Ltd.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Beta Interferon Market by Type, Route of Administration, Application, Distribution Channel - Global Forecast 2025-2030 - Product Image

Beta Interferon Market by Type, Route of Administration, Application, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 199 Pages
  • Global
From
Beta Interferon - Global Strategic Business Report - Product Image

Beta Interferon - Global Strategic Business Report

  • Report
  • 93 Pages
  • Global
From
Interferon Market by Type, Category, Distribution Channel, Application - Global Forecast 2025-2030 - Product Image

Interferon Market by Type, Category, Distribution Channel, Application - Global Forecast 2025-2030

  • Report
  • 198 Pages
  • Global
From
Interferon - Global Strategic Business Report - Product Image

Interferon - Global Strategic Business Report

  • Report
  • 78 Pages
  • Global
From
Interferons Market Report 2025 - Product Image

Interferons Market Report 2025

  • Report
  • 175 Pages
  • Global
From

About the Beta Interferon Market

Beta Interferon is a type of biotechnology drug used to treat multiple sclerosis (MS). It is a synthetic form of a naturally occurring protein that helps to reduce inflammation and slow the progression of MS. Beta Interferon is administered through injections and is used to reduce the frequency of MS relapses. It is also used to reduce the severity of symptoms and slow the progression of disability. Beta Interferon is one of the most widely used treatments for MS, and is often prescribed in combination with other therapies. It is also used to treat other neurological conditions, such as chronic inflammatory demyelinating polyneuropathy. The Beta Interferon market is highly competitive, with several major players offering a range of products. Companies in the market include Biogen, Merck, Novartis, Sanofi, and Teva Pharmaceuticals. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.